DermNexus Session Examines Targeted Dermatology Therapies, Safety, Shared Decisions

Targeted immunomodulatory therapies and selective pathway inhibitors are reshaping dermatologic care for complex conditions like chronic spontaneous urticaria and psoriatic arthritis, as clinicians address nuanced safety profiles, individual patient risks, and pretreatment screening protocols.

The opening DermNexus session examined how emerging medical dermatology treatments require careful management of patient comorbidities and immunologic mechanisms, Dermatology Times reported. Clinicians at the session addressed the complexities of selecting targeted therapies when dealing with patients who have experienced inadequate responses to conventional treatments.

Newer Drugs Target Specific Pathways

  • Targeted Inhibition: Newer drugs focus on specific cellular pathways rather than broad inflammation, helping doctors tailor treatments for stubborn skin and joint diseases.
  • Pretreatment Screening: Comprehensive safety checks—including tuberculosis tests and infection risk assessments—are mandatory before starting these powerful medications.
  • Shared Decision-Making: Physicians and patients must weigh individual risk factors, lifestyle preferences, and prior treatment histories together.

Evaluating Risk Profiles in Oral JAK Inhibitors

Safety findings derived from rheumatoid arthritis populations may not fully reflect younger dermatology cohorts who present with different baseline comorbidities and cardiovascular risk factors. Adverse events discussed among dermatologic patients included respiratory infections, herpes zoster, nausea, and acne.

“Do I talk about cardiovascular disease in oral JAK patients? Absolutely, because I’m not going to hide anything,” Butler said. He emphasized that clinicians carry a distinct responsibility to explain potential risks while helping individuals understand how those risks apply to their specific circumstances.

“It’s our responsibility to say, hey, I’m going to walk with you. Here are the risks of any medication I’m going to give you,” Butler said. Proper pretreatment screening, laboratory monitoring, infection risk assessment, and shared decision-making remain essential when initiating targeted immunomodulatory therapies, as outlined in clinical evaluation data.

Mechanistic Evolution in Selective TYK2 and BTK Inhibition

Selective TYK2 inhibition differs from broader JAK inhibition in both mechanism and therapeutic targeting, despite participating in related intracellular cytokine signaling processes. Instead of competing directly at the active site, specific selective TYK2 inhibitors engage a regulatory domain on the enzyme.

The session also explored BTK inhibition as a treatment strategy for chronic spontaneous urticaria, particularly among patients continuing to experience symptoms despite established therapies. BTK contributes to intracellular signaling involved in mast-cell activation, a central process in the development of wheals, itching, and angioedema.

Aldredge presented a case involving a patient with persistent chronic spontaneous urticaria despite previous treatment with antihistamines, omalizumab, and cyclosporine, prompting discussion of alternative approaches such as remibrutinib. The discussion also addressed potential bruising or bleeding, drug interactions, and management around procedures, supported by recent clinical investigation data.

Managing Refractory Psoriatic Disease

A second clinical case examined a 44-year-old patient with a 20-year history of psoriasis and psoriatic arthritis who experienced substantial disease activity despite methotrexate and multiple biologic agents. The individual displayed an estimated 18% body surface area affected, involvement of the scalp and nails, alongside ongoing joint complaints such as swelling, tenderness, and dactylitis.

Focusing on intracellular signaling pathways rather than concentrating solely on individual inflammatory mediators was underscored by Seiter as a potential benefit. He explained that intracellular inhibition may affect signaling from multiple inflammatory pathways, potentially offering an alternative approach when highly targeted treatments fail to control disease activity.

Aldredge emphasized the importance of evaluating the patient’s complete clinical profile, noting that a favorable cardiovascular risk profile, absence of smoking history, and lack of previous venous thromboembolism or malignancy contributed to treatment suitability. Faculty reviewed evidence supporting upadacitinib in biologic-experienced patients, building on foundational plaque psoriasis trial outcomes.

Therapeutic Target Primary Pathway Role Key Clinical Consideration
JAK / TYK2 Intracellular cytokine signaling Cardiovascular risk and infection screening
BTK Mast-cell activation in urticaria Monitoring for bruising, bleeding, and drug interactions
OX40 / OX40L Atopic dermatitis immune axis Evaluating long-term safety and patient comorbidities

Screen for Infections Before Starting Therapy

Patients considering targeted immunomodulatory therapies must undergo rigorous screening for latent infections, including tuberculosis, prior to initiation. Individuals with active systemic infections, a history of venous thromboembolism, specific cardiovascular risk factors, or those currently planning pregnancy must discuss absolute and relative contraindications with their multidisciplinary care team. Consult a healthcare provider immediately if signs of infection—such as persistent fever, localized skin lesions, or respiratory distress—develop during therapy.

Understanding immunologic mechanisms helps clinicians interpret efficacy and safety findings, evaluate emerging treatment options, and individualize care for patients with refractory dermatologic conditions. Investigations into the OX40 ligand axis continue to illustrate how pathway-based reasoning applies to real-world treatment decisions.

References

  • Guttman-Yassky E, Croft M, Geng B, et al. The role of OX40 ligand/OX40 axis signalling in atopic dermatitis. Br J Dermatol. 2024;191(4):488-496.
  • Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021;80(3):312-320.
  • Metz M, Giménez-Arnau A, Hide M, et al. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392:984-994.
  • Armstrong AW, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023.

Disclaimer: This article is intended for informational and educational purposes only and should not replace professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified physician with any questions regarding a medical condition.

Photo of author

Health Desk

Health Desk at Archyde.

Kim Hye-soo Returns to 2026 MAMA Awards Stage in Osaka

257 Beer Kegs Test New Špindlerův Mlýn Cable Car